Intermittent chemotherapy in metastatic androgen-independent prostate cancer

Intermittent use of chemotherapy for androgen-independent prostate cancer (AIPC) instead of treatment until disease progression may reduce toxicity. We prospectively tested this approach in eight AIPC patients responding to calcitriol plus docetaxel who reached a serum prostate-specific antigen (PSA...

Descripción completa

Detalles Bibliográficos
Autores principales: Beer, T M, Garzotto, M, Henner, W D, Eilers, K M, Wersinger, E M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376967/
https://www.ncbi.nlm.nih.gov/pubmed/12966410
http://dx.doi.org/10.1038/sj.bjc.6601232
Descripción
Sumario:Intermittent use of chemotherapy for androgen-independent prostate cancer (AIPC) instead of treatment until disease progression may reduce toxicity. We prospectively tested this approach in eight AIPC patients responding to calcitriol plus docetaxel who reached a serum prostate-specific antigen (PSA) <4 ng ml(−1). Chemotherapy was suspended until a rise in PSA⩾50% and 1 ng ml(−1). The median duration of treatment holiday was 20 weeks (13–43+weeks) and all patients retained sensitivity to re-treatment. Chemotherapy holiday was associated with an improvement of fatigue (P=0.05). Intermittent chemotherapy for AIPC is feasible and deserves further study.

Ejemplares similares